Rhythm Pharmaceuticals, Inc. RYTM Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $189.76M+45.8% | $130.13M+68.1% | $77.43M+228% | $23.64M+649% | ||
| $19.49M+45.8% | $13.37M+43.7% | $9.3M+336% | $2.13M+256% | ||
| $170.27M+45.8% | $116.76M+71.4% | $68.13M+217% | $21.51M+742% | ||
| 89.7%0.0pp | 89.7%+1.7pp | 88%-3.0pp | 91%+10.0pp | ||
| $167.34M-29.7% | $237.96M+76.3% | $134.95M+24.2% | $108.63M+4.3% | ||
| $194.94M+35.1% | $144.3M+22.8% | $117.53M+27.7% | $92.03M+34.4% | ||
| $381.77M-3.5% | $395.63M+51.1% | $261.78M+29.1% | $202.8M+17.1% | ||
| -$192.02M+27.7% | -$265.51M-44.0% | -$184.35M-2.9% | -$179.16M-5.3% | ||
| -101.2%+103pp | -204%+34.1pp | -238.1%+520pp | -757.9%+4,634pp | ||
| $20.58M+2.7% | $20.05M+42.6% | $14.06M+170% | $5.2M— | ||
| $15.29M+4.0% | $14.71M+5.5% | $13.95M+217% | $4.4M+883% | ||
| -$4.03M— | —— | —— | -$1.96M-102% | ||
| -$196.04M+24.7% | -$260.22M-41.3% | -$184.11M— | —— | ||
| $528K— | —— | —— | —— | ||
| -$196.54M+24.6% | -$260.57M-41.1% | -$184.68M-2.0% | -$181.12M-160% | ||
| -103.6%+96.7pp | -200.2%+38.3pp | -238.5%+528pp | -766.2%+1,441pp | ||
| -$3.11+28.5% | -$4.35-35.9% | -$3.20+7.8% | -$3.47-155% | ||
| -$3.11+28.5% | -$4.35-35.9% | -$3.20+7.8% | -$3.47-159% | ||
| 258M+6.0% | 243.4M+6.2% | 229.1M+12.2% | 204.2M+2.9% | ||
| 258M+6.0% | 243.4M+6.2% | 229.1M+12.2% | 204.2M+3.3% | ||
| -$202.67M+23.4% | -$264.71M-43.5% | -$184.45M-1.8% | -$181.21M-161% | ||
| $5.38M+35.5% | $3.97M— | $0— | —— | ||
| $15.29M+4.0% | $14.71M+5.5% | $13.95M+217% | $4.4M+883% | ||
| $504K+388% | -$175K-148% | $366K— | —— | ||
| -$1.27M-63,700% | $2K+101% | -$140K— | —— | ||
| $1.26M-43.6% | $2.24M+529% | $356K+131% | -$1.16M-101% | ||
| $189.76M+45.8% | $130.13M— | —— | $23.64M— | ||
| -$192.02M+27.7% | -$265.51M-44.0% | -$184.35M-2.9% | -$179.16M-5.3% | ||
| —— | —— | —— | —— | ||
| -$192.02M+27.7% | -$265.51M-44.0% | -$184.35M-2.9% | -$179.16M-5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated $217.2M in revenue over the trailing twelve months, up 58.7% year over year.
- Is Rhythm Pharmaceuticals, Inc. profitable?
- Rhythm Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $202.7M over the trailing twelve months, a -93.3% net margin.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 89.4% and operating margin is -90.9%, with a -93.3% net margin.
- What is Rhythm Pharmaceuticals, Inc.'s earnings per share?
- Rhythm Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-3.13.
- Where does Rhythm Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
